Cerebrolysin in mild-to-moderate Alzheimer’s disease: 28-week placebo-controlled trial
Ruether E, Husmann R, Kinzler E · 2001 · International Clinical Psychopharmacology
Reported findings and study design
Double-blind trial. 76 assigned to Cerebrolysin and 73 to placebo. Intravenous 30 mL five days weekly for four weeks, repeated after a two-month treatment-free interval.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| ADAS-Cog at week 16 | 3.2-point difference favoring Cerebrolysin (p<0.0001). | |
| Global clinical response at week 16 | 63.5% versus 41.4% on the Clinical Global Impression scale (p<0.004). | |
| Any adverse event | 43% with Cerebrolysin and 38% with placebo. |
The trial followed patients for 28 weeks and does not establish a lasting effect on disease progression.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The trial followed patients for 28 weeks and does not establish a lasting effect on disease progression.
Related publications may cover the same research program or participants.
Source access
Original abstract checked for selected methods and findings.
Source reviewed 2026-11-12.
Source type: Journal publication
Citation and original source
Original source: Ruether E, Husmann R, Kinzler E. Cerebrolysin in mild-to-moderate Alzheimer’s disease: 28-week placebo-controlled trial International Clinical Psychopharmacology 2001.
Molekul research summary: https://molekul.io/research/cerebrolysin-alzheimers-rct-2001. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry